Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S.708 - legislation to require a dear Medicaid director letter concerning precision medicine for depression. Regulations governing Medicare Advantage plans and the use of prior authorization.
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2026 · first_quarter · Q1
Prior authorization issues in Medicare Advantage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2025 · fourth_quarter · Q4
Source: Senate LDA
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S.708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression. Regulations governing Medicare Advantage plans and the use of prior authorization.
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Client: MYRIAD GENETICS, INC. · Firm: MYRIAD GENETICS, INC.
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
Congressional oversight of Medicare Advantage and prior authorization issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2025 · third_quarter · Q3
Congressional oversight of Medicare Advantage and prior authorization issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2025 · second_quarter · Q2
Congressional oversight of Medicare Advantage and prior authorization misuses.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2025 · first_quarter · Q1
Congressional oversight of Medicare Advantage and prior authorization misuses.
Commercial coverage decisions impacting biomarker testing in mental health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2024 · fourth_quarter · Q4
S.708 - legislation to require a dear Medicaid director letter concerning precision medicine for depression. Regulations governing Medicare Advantage plans and the use of prior authorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2024 · third_quarter · Q3
S.708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression. Regulations governing Medicare Advantage plans and the use of prior authorization.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2024 · second_quarter · Q2
FDA rulemaking to regulate laboratory developed tests
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via MYRIAD GENETICS, INC.
2024 · first_quarter · Q1
S708 - legislation to require CMS to issue a dear Medicaid director letter concerning precision medicine for depression Regulations governing Medicare Advantage plans and the use of prior authorization
FDA rulemaking to regulate laboratory developed tests
Filing targets: HOUSE OF REPRESENTATIVES, SENATE